Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-31T14:46:54.289Z Has data issue: false hasContentIssue false
  • English
  • Français

Enhanced growth hormone responses to pyridostigmine challenge in patients with panic disorder

Published online by Cambridge University Press:  03 January 2018

J. M. Cooney ,
J. V. Lucey  and
T. G. Dinan
J. M. Cooney*
Affiliation:
Department of Psychological Medicine, St Bartholomew's Hospital, London
J. V. Lucey
Affiliation:
Department of Psychological Medicine, St Bartholomew's Hospital, London
T. G. Dinan
Affiliation:
Department of Psychological Medicine, St Bartholomew's Hospital, London
*
Dr. J. M. Cooney, Department of Psychological Medicine, St Bartholomew's Hospital, West Smithfield, London ECIA 7BE. Fax: 0171-601 7969
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Panic disorder is associated with neuroendocrinological abnormalities, some of which overlap with those seen in major depression. To date, there has been little assessment of the role of cholinergic mechanisms in this disorder.

Method

Sixteen patients with DSM–III–R panic disorder and an age and gender-matched comparison group were administered 120 mg of the acetylcholinesterase inhibitor pyridostigmine. Growth hormone (GH) responses over a three-hour period were monitored.

Results

Mean ΔGH, the difference between basal and the maximum pyridostigmine levels, was significantly greater in patients with panic disorder than in the comparison group.

Conclusions

This may reflect increased cholinergic responsivity in panic disorder.

Type
Papers
Information
The British Journal of Psychiatry , Volume 170 , Issue 2 , February 1997 , pp. 159 - 161
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, (3rd edn. revised) (DSM-III-R). Washington, DC: APA.Google Scholar
Coplan, J. D., Papp, L. A., Martinez, J. A., et al (1995) Persistence of blunted human growth hormone response to clonidine in fluoxetine treated patients with panic disorder. American Journal of Psychiatry, 152, 619–622.Google Scholar
Devesa, J., Barros, M. G., Gondar, M., et al (1995) Regulation of hypothalamic somatostatin by glucocorticoids. Journal of Steroid Biochemistry and Molecular Biology, 53, 277–282.Google Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry, 23, 56–62.Google Scholar
Janowsky, D. S. & Overstreet, D. H. (1995) The role of acetylcholine mechanisms in mood disorders. In Psychopharmacology The Fourth Generation of Progress (eds Bloom, F. E. & Kupfer, D. J.). pp. 945–956. New York: Raven Press.Google Scholar
Lesser, I. M. (1990) Panic disorder and depression: Cooccurrence and treatment. In Clinical Aspects of Panic Disorder (ed Ballenger, J. C.) pp 181–191. New York: Wiley Liss.Google Scholar
Mitchell, P. B., Beam, J. A., Corn, T. H. et al (1981) Growth hormone response to clonidine after recovery in patients with endogenous depression. British Journal of Psychiatry, 152, 34–38.CrossRefGoogle Scholar
O'Kenne, V., O'Flynn, M., Lucey, J., et al (1992) Pyridostigmine-induced growth homrrane responses in healthy and depressed subjects: Evidence for cholinergic supersensitivity in depression. Psychological Medicine, 22, 55–60.CrossRefGoogle Scholar
Ross, R. J., Tsagarakis, S., Grossman, A. et al (1987) GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: Studies with pyridostigmine and GHRH. Clinical Endocrinology, 27, 727–733.CrossRefGoogle ScholarPubMed
Stein, M. B. & Uhde, T. W. (1990) Panic disorder and major depression: Lifetime relationship and biological markers. In Clinical Aspects of Panic Disorder (ed. Ballenger, J. C.), pp 151–168. New York: Wiley Liss.Google Scholar
Trainer, P. J., Kirk, M. W. Sevage, M. D. et al (1992) Pyridostigmine partially reverses dexamethasone induced inhibition of the growth hornrtorve response to growth hormone-releasing hormone. Journal of Endocrinology, 134, 513–517.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.